|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-2-22
|
|
pubmed:abstractText |
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by dysregulated tubular epithelial cell growth, resulting in the formation of multiple renal cysts and progressive renal failure. To date, there is no effective treatment for ADPKD. The mammalian target of rapamycin (mTOR) is an atypical protein kinase and a central controller of cell growth and proliferation. We examined the effect of the mTOR inhibitor sirolimus (rapamycin) on renal functional loss and cyst progression in the Han:SPRD rat model of ADPKD.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Biological Markers,
http://linkedlifedata.com/resource/pubmed/chemical/Creatinine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunosuppressive Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/Ribosomal Protein S6 Kinases, 70-kDa,
http://linkedlifedata.com/resource/pubmed/chemical/Sirolimus,
http://linkedlifedata.com/resource/pubmed/chemical/TOR Serine-Threonine Kinases,
http://linkedlifedata.com/resource/pubmed/chemical/mTOR protein, rat,
http://linkedlifedata.com/resource/pubmed/chemical/ribosomal protein S6 kinase, 70kD...
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0931-0509
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
598-604
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16221708-Administration, Oral,
pubmed-meshheading:16221708-Animals,
pubmed-meshheading:16221708-Biological Markers,
pubmed-meshheading:16221708-Blood Urea Nitrogen,
pubmed-meshheading:16221708-Creatinine,
pubmed-meshheading:16221708-Disease Models, Animal,
pubmed-meshheading:16221708-Disease Progression,
pubmed-meshheading:16221708-Immunosuppressive Agents,
pubmed-meshheading:16221708-Male,
pubmed-meshheading:16221708-Phosphorylation,
pubmed-meshheading:16221708-Polycystic Kidney, Autosomal Dominant,
pubmed-meshheading:16221708-Protein Kinases,
pubmed-meshheading:16221708-Rats,
pubmed-meshheading:16221708-Rats, Sprague-Dawley,
pubmed-meshheading:16221708-Ribosomal Protein S6 Kinases, 70-kDa,
pubmed-meshheading:16221708-Sirolimus,
pubmed-meshheading:16221708-TOR Serine-Threonine Kinases,
pubmed-meshheading:16221708-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).
|
|
pubmed:affiliation |
Physiological Institute, University Zürich-Irchel, Zürich, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
